Loading…
Bolt Biotherapeutics, Inc. is projected to decline to $5.21 by 2027, a -1% move from its current price of $5.29. BOLT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.08 | $5.29 | $5.51 | +0.04% |
| May 30 | $4.99 | $5.29 | $5.60 | +0.07% |
| May 31 | $4.93 | $5.29 | $5.68 | +0.11% |
| Jun 1 | $4.88 | $5.29 | $5.74 | +0.15% |
| Jun 2 | $4.84 | $5.29 | $5.80 | +0.18% |
| Jun 3 | $4.80 | $5.30 | $5.85 | +0.22% |
| Jun 4 | $4.76 | $5.30 | $5.90 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.76 | $5.30 | $5.90 | +0.26% |
| Week 2 | $4.56 | $5.31 | $6.18 | +0.52% |
| Week 3 | $4.42 | $5.33 | $6.42 | +0.78% |
| Week 4 | $4.31 | $5.34 | $6.62 | +1.04% |
| Week 5 | $4.21 | $5.35 | $6.81 | +1.30% |
| Week 6 | $4.13 | $5.37 | $6.98 | +1.56% |
| Week 7 | $4.05 | $5.38 | $7.15 | +1.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel immunotherapies for the treatment of cancer. Its pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc.
in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Bolt Biotherapeutics, Inc. (BOLT) is a stock trading at $4.95 per share with a market cap of $9.51M. It holds a rank of 5163 among listed securities. The current price and market position sit alongside a multi year outlook that envisions upside from a series of year by year targets.
The forecast lists a path from the current level to higher values through 2050, with varying min, avg and max prices and rising average prices over time. The outlook includes year by year targets such as 2026, 2029, 2030, 2040 and 2050, with increasing averages and corresponding ROIs that imply a longer term upside potential.
A major floor 26.0% below — a decisive break under it would weaken the trend.
The nearest floor, 17.5% below — buyers have tended to step in here.
Price is pressing into resistance (2.0% away) — a breakout level to watch.
A major ceiling 34.2% above — clearing it would confirm fresh momentum.
Key BOLT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BOLT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.91 | Buy | $5.01 | Buy |
| MA 10 | $4.83 | Buy | $4.89 | Buy |
| MA 20 | $4.80 | Buy | $4.83 | Buy |
| MA 50 | $4.72 | Buy | $4.81 | Buy |
| MA 100 | $5.05 | Buy | $4.95 | Buy |
| MA 200 | $5.19 | Buy | $5.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.03 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 186.72 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 13.17 | Buy |
| Bollinger %B (20,2) | 1.06 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 64.10 | Neutral |
| Momentum (10) | 0.50 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 5.13 | Buy |
| ADX (14) | 8.40 | Neutral |
| ATR (14) | 0.18 | Info |
The 30 day technical picture is neutral. RSI14 is 50. The SMA50 is $4.68 and the SMA200 is $5.19. Support is at $4.36 and resistance is at $5.39. The 30 day range runs from a low of $3.76 to a high of $6.53.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.91 | $5.29 | $6.89 | 0% | Neutral | |
| $3.93 | $5.21 | $7.40 | -1% | Neutral | |
| $4.11 | $5.68 | $8.48 | +7% | Neutral | |
| $5.14 | $7.36 | $11.43 | +39% | Bullish | |
| $5.28 | $7.82 | $12.54 | +48% | Bullish | |
| $4.97 | $7.59 | $12.51 | +44% | Bullish | |
| $4.61 | $7.23 | $12.23 | +37% | Bullish | |
| $4.27 | $6.88 | $11.91 | +30% | Bullish | |
| $5.06 | $8.37 | $14.79 | +58% | Bullish | |
| $5.83 | $9.88 | $17.80 | +87% | Bullish | |
| $5.87 | $11.20 | $21.85 | +112% | Bullish | |
| $9.87 | $21.94 | $47.99 | +315% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.91 | $5.29 | $6.21 | +0.00% |
| June 2026 | $4.45 | $5.29 | $6.47 | +0.05% |
| July 2026 | $4.55 | $5.47 | $6.82 | +3.37% |
| August 2026 | $4.37 | $5.31 | $6.72 | -2.92% |
| September 2026 | $4.24 | $5.19 | $6.66 | -2.11% |
| October 2026 | $4.42 | $5.45 | $7.06 | +4.95% |
| November 2026 | $4.45 | $5.52 | $7.23 | +1.34% |
| December 2026 | $4.18 | $5.22 | $6.89 | -5.52% |
Click any year to see its month-by-month BOLT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BOLT price prediction for 2026 points to an average of $5.29 (low $3.91, high $6.89) — a potential gain of 0% on today's $5.29. Price action looks broadly range-bound.
In 2027, BOLT is projected to trade between $3.93 and $7.40, averaging $5.21 — a potential decline of -1% from today's $5.29. That is -1% versus the projected 2026 average. A consolidation phase looks the most probable path here.
Bolt Biotherapeutics, Inc.'s 2028 outlook centres on $5.68, within a $4.11 to $8.48 range. That is up +9% on the projected 2027 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2029, BOLT could reach as high as $11.43, with a base case around $7.36 and support toward $5.14 — roughly +39% from $5.29. Buyers look set to stay in control over this stretch.
Expect BOLT to range from $5.28 to $12.54 through 2030. The $7.82 average target implies a +48% move from current prices. That is up +6% on the projected 2029 average. Momentum favours further upside here.
The BOLT price prediction for 2031 points to an average of $7.59 (low $4.97, high $12.51) — a potential gain of +44% on today's $5.29. Buyers look set to stay in control over this stretch.
In 2032, BOLT is projected to trade between $4.61 and $12.23, averaging $7.23 — a potential gain of +37% from today's $5.29. That is -5% versus the projected 2031 average. Momentum favours further upside here.
Bolt Biotherapeutics, Inc.'s 2033 outlook centres on $6.88, within a $4.27 to $11.91 range. That is -5% versus the projected 2032 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BOLT could reach as high as $14.79, with a base case around $8.37 and support toward $5.06 — roughly +58% from $5.29. Momentum favours further upside here.
Expect BOLT to range from $5.83 to $17.80 through 2035. The $9.88 average target implies a +87% move from current prices. That is up +18% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The BOLT price prediction for 2040 points to an average of $11.20 (low $5.87, high $21.85) — a potential gain of +112% on today's $5.29. Momentum favours further upside here.
In 2050, BOLT is projected to trade between $9.87 and $47.99, averaging $21.94 — a potential gain of +315% from today's $5.29. That is up +96% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BOLT today (≈ 189.214759 BOLT) could be worth
$4,152.17
+$3,152.17 (+315%) by 2050 · US Dollar
Based on the average projected BOLT price of $21.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BOLTwould be worth at today's price.
$1,000 invested in BOLT on May 27, 2025 (≈ 156.249998 BOLT) would be worth
$825.78
-$174.22 (-17.4%) today · 0.83× · US Dollar
Based on a BOLT entry price of $6.4 vs. today's $5.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.61 | $1,146.42 | +14.6% |
| 1 month ago | $4.96 | $1,065.52 | +6.6% |
| 3 months ago | $4.63 | $1,141.47 | +14.1% |
| 6 months ago | $5.07 | $1,042.41 | +4.2% |
| 1 year ago | $6.4 | $825.78 | -17.4% |
| All time (5.0y) ago | $332.2 | $15.91 | -98.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BOLT forecast.
Our base-case forecast reaches $11.00 around 2040.
Implied market cap at $11.00: $21.14M
The multi year forecast shows a bullish path with rising averages and larger upside potential into the 2030s and 2040s. The 2030 average price is $7.58 with a 53.2 in the ROI field. The 2040 average price is $10.94 with a 121 ROI.
The 2050 average price is $21.42 with a 332.7 ROI. The 2029 average price is $7.08 with a 43 ROI and the 2035 average price is $9.65 with a 95 ROI. The forecast also shows 2026 average price of $4.95 and 2034 average price of $8.12 with a 64 ROI.
These figures imply an upward trajectory over the long term, but they are estimates and not guarantees. The forecast also notes the asset remains exposed to volatility with annualized volatility of 80%.
Tap a question to reveal the answer.
2030 min $5.07, avg $7.58, max $12.27; ROI 53.2; sentiment BULLISH.
Forecasts show rising averages and bullish sentiment in the later years, with 2030, 2040 and 2050 averages of $7.58, $10.94 and $21.42 and ROIs of 53.2, 121 and 332.7 respectively, but these are estimates and not guarantees.
No. The forecast max by 2050 is $47.54.
Current price $4.95 and market cap $9.51M.
30 day range low $3.76, high $6.53.
Bolt Biotherapeutics, Inc. Community Discussion
0Share your Bolt Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.